a month ago
XNCR
AnalystsEtzer DaroutEtzer Darout's Stock Forecasts
AnalystsEtzer Darout
Sectors:
Analyst Ranking
Top 3%
#134 out of 5177 analysts
Average Return
+30.03%
Win Rate
53%77 out of 145
Risk vs Reward
Poor
Good
Etzer Darout's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Terns Pharmaceuticals IncTERN | +1,162.07% | $2.90 | $36.60 | 2025-05-12 - 2026-01-16 | Buy |
Five Prime Therapeutics IncFPRX | +884.42% | $3.85 | $37.90 | 2020-09-21 - 2021-03-09 | Strong Buy |
Terns Pharmaceuticals IncTERN | +394.59% | $7.40 | $36.60 | 2025-09-16 - 2026-01-16 | Strong Buy |
Terns Pharmaceuticals IncTERN | +349.63% | $8.14 | $36.60 | 2025-10-21 - 2026-01-16 | Strong Buy |
Scholar Rock Holding CorpSRRK | +278.17% | $8.45 | $31.96 | 2024-08-08 - 2025-08-08 | Buy |
Etzer Darout Analyst Color
Get additional color on Etzer Darout's coverage of popular stocks
a month ago
SRRK
a month ago
PTGX
a month ago
IOVA
a month ago
ARVN
a month ago
KYMR
2 months ago
SNDX
2 months ago
KURA
2 months ago
IOVA
2 months ago
INCY
2 months ago
SRRK
2 months ago
JANX
2 months ago
KYMR
3 months ago
XNCR
3 months ago
RAPT
3 months ago
CTMX
4 months ago
CCCC
5 months ago
IVA
9 months ago
VERV
Etzer Darout's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Xencor IncXNCR | 8 | Strong Buy | $26.00 | +103.28% | Maintains | a month ago |
Scholar Rock Holding CorpSRRK | 8 | Strong Buy | $52.00 | +15.63% | Maintains | a month ago |
Protagonist Therapeutics IncPTGX | 5 | Strong Buy | $108.00 | +31.72% | Maintains | a month ago |
Janux Therapeutics IncJANX | 3 | Strong Buy | $29.00 | +110.76% | Maintains | a month ago |
Iovance Biotherapeutics IncIOVA | 2 | Strong Buy | $10.00 | +323.73% | Maintains | a month ago |
Celldex Therapeutics IncCLDX | 3 | Strong Sell | $24.00 | -6.43% | Maintains | a month ago |
C4 Therapeutics IncCCCC | 6 | Strong Buy | $5.00 | +124.22% | Maintains | a month ago |
Arvinas IncARVN | 7 | Strong Buy | $18.00 | +47.54% | Maintains | a month ago |
Anaptysbio IncANAB | 3 | Strong Buy | $55.00 | +20.40% | Maintains | a month ago |
Summit Therapeutics IncSMMT | 3 | Hold | $18.00 | +5.63% | Upgrades | a month ago |
Terns Pharmaceuticals IncTERN | 11 | Strong Buy | $56.00 | +53.01% | Maintains | a month ago |
Kymera Therapeutics IncKYMR | 4 | Strong Buy | $119.00 | +71.12% | Maintains | a month ago |
Syndax Pharmaceuticals IncSNDX | 1 | Strong Buy | $35.00 | +70.57% | Maintains | 2 months ago |
Kura Oncology IncKURA | 1 | Strong Buy | $28.00 | +230.97% | Maintains | 2 months ago |
Incyte CorpINCY | 1 | Strong Buy | $115.00 | +8.28% | Maintains | 2 months ago |
Rapt Therapeutics IncRAPT | 3 | Strong Buy | $56.00 | +59.54% | Maintains | 2 months ago |
Exelixis IncEXEL | 5 | Hold | $41.00 | -6.73% | Maintains | 2 months ago |
Cytomx Therapeutics IncCTMX | 10 | Strong Buy | $6.00 | +11.32% | Maintains | 3 months ago |
Tvardi Therapeutics IncTVRD | 1 | Strong Buy | $61.00 | +1,234.79% | Initiates Coverage On | 3 months ago |
Oruka Therapeutics IncORKA | 1 | Strong Buy | $48.00 | +43.71% | Initiates Coverage On | 3 months ago |
Monopar TherapeuticsMNPR | 1 | Strong Buy | $125.00 | +78.57% | Initiates Coverage On | 3 months ago |
Corvus Pharmaceuticals IncCRVS | 1 | Strong Buy | $16.00 | +98.76% | Initiates Coverage On | 3 months ago |
Abivax SaABVX | 1 | Strong Buy | $142.00 | +21.26% | Initiates Coverage On | 3 months ago |
Merus NvMRUS | 8 | Hold | $97.00 | +7.78% | Downgrades | 4 months ago |
Macrogenics IncMGNX | 9 | Strong Buy | $3.00 | +74.42% | Assumes | 4 months ago |
Inventiva SaIVA | 4 | Strong Buy | $13.00 | +99.69% | Maintains | 5 months ago |
Verve Therapeutics IncVERV | 1 | Strong Buy | $24.00 | +115.63% | Maintains | 9 months ago |
Biontech SeBNTX | 4 | Buy | $143.00 | +31.19% | Maintains | 10 months ago |
Q32 Bio IncQTTB | 3 | Hold | $3.00 | -16.67% | Downgrades | a year ago |
Igm Biosciences IncIGMS | 2 | Hold | $2.00 | N/A | Downgrades | a year ago |
Tourmaline Bio IncTRML | 1 | Buy | $50.00 | N/A | Initiates Coverage On | a year ago |
Nurix Therapeutics IncNRIX | 1 | Buy | $35.00 | N/A | Initiates Coverage On | a year ago |
Jasper Therapeutics IncJSPR | 1 | Buy | $63.00 | N/A | Initiates Coverage On | a year ago |
Acrivon Therapeutics IncACRV | 7 | Buy | $27.00 | N/A | Maintains | a year ago |
Nuvalent IncNUVL | 6 | Buy | $134.00 | N/A | Maintains | a year ago |
Genmab AGMAB | 3 | Buy | $48.00 | N/A | Reiterates | a year ago |
Novartis AgNVS | 3 | Hold | $120.00 | N/A | Maintains | a year ago |
Y Mabs Therapeutics IncYMAB | 5 | Buy | $25.00 | N/A | Maintains | a year ago |
Fate Therapeutics IncFATE | 7 | Hold | $6.00 | N/A | Maintains | 2 years ago |
Astrazeneca PLCAZN | 4 | Buy | $82.00 | N/A | Maintains | 2 years ago |
Immunogen IncIMGN | 4 | Hold | $31.00 | N/A | Downgrades | 2 years ago |
Foghorn Therapeutics IncFHTX | 2 | Buy | $19.00 | N/A | Maintains | 3 years ago |
Seagen IncSGEN | 4 | Hold | $229.00 | N/A | Downgrades | 3 years ago |
Alnylam Pharmaceuticals IncALNY | 2 | Strong Buy | $170.00 | N/A | Upgrades | 4 years ago |
Traws Pharma IncTRAW | 1 | Strong Buy | $60.00 | N/A | Initiates Coverage On | 5 years ago |
Five Prime Therapeutics IncFPRX | 2 | Hold | $38.00 | N/A | Downgrades | 5 years ago |
Akero Therapeutics IncAKRO | 1 | Strong Buy | $54.00 | N/A | Initiates Coverage On | 5 years ago |
Eidos Therapeutics IncEIDX | 2 | Hold | N/A | N/A | Downgrades | 5 years ago |
Mirum Pharmaceuticals IncMIRM | 1 | Strong Buy | $38.00 | N/A | Maintains | 5 years ago |
Aclaris Therapeutics IncACRS | 1 | Buy | $52.00 | N/A | Maintains | 8 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.